Given the strong association between CDKN2A and FAC, we indicated that regulating pathways involved in CDKN2A-associated genes or designing novel metal-based anticancer agents to induce ferroptosis and cuproptosis may guide us to develop new anti-cancer treatment strategies. The gene discussed is CDKN2A; the disease is cancer.